2023
Effect of Burosumab on Muscle Function and Strength, and Rates of ATP Synthesis in Skeletal Muscle in Adults With XLH
Insogna K, Sullivan R, Parziale S, Deng Y, Carrano D, Simpson C, Dufour S, Carpenter T, Petersen K. Effect of Burosumab on Muscle Function and Strength, and Rates of ATP Synthesis in Skeletal Muscle in Adults With XLH. The Journal Of Clinical Endocrinology & Metabolism 2023, 109: e1061-e1071. PMID: 37930769, DOI: 10.1210/clinem/dgad642.Peer-Reviewed Original ResearchSymptoms of painMuscle function testsFunction testsMuscle strengthMuscle functionSkeletal muscleLower extremity joint painSTS testMuscle function studiesImproved muscle functionTreatment-naïve adultsSynthesis rateMonths of studyJoint painThird doseSymptomatic adultsClinical trialsRight calfATP synthesis rateBurosumabPainMuscle concentrationsXLHSymptomsMuscle
2021
Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey Data
Javaid MK, Ward L, Pinedo-Villanueva R, Rylands AJ, Williams A, Insogna K, Imel EA. Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey Data. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: e1249-e1262. PMID: 34636401, PMCID: PMC8852215, DOI: 10.1210/clinem/dgab739.Peer-Reviewed Original ResearchConceptsMusculoskeletal featuresClinical trialsHistory of fractureClinical Trials GroupAge 20 yearsClinical trial subjectsProportion of adultsMusculoskeletal manifestationsPain subgroupsSpinal stenosisGroup of adultsOverall prevalenceTrial groupLow prevalenceAge bandsTrial subjectsOnline survey participantsAdultsAgeSurgeryHigh ratePrevalenceXLHTrialsSurvey participants
2020
New Therapies for Hypophosphatemia-Related to FGF23 Excess
Athonvarangkul D, Insogna KL. New Therapies for Hypophosphatemia-Related to FGF23 Excess. Calcified Tissue International 2020, 108: 143-157. PMID: 32504139, DOI: 10.1007/s00223-020-00705-3.BooksConceptsTumor-induced osteomalaciaCutaneous skeletal hypophosphatemia syndromeEpidermal nevus syndromeAutosomal dominant hypophosphatemic ricketsAutosomal recessive hypophosphatemic ricketsHypophosphatemic ricketsForms of FGF23Treatment of XLHActive comparator trialsMainstay of therapyMonoclonal blocking antibodyNew treatment modalitiesMcCune-Albright syndromeRenal phosphate wastingRecessive hypophosphatemic ricketsDominant hypophosphatemic ricketsFGF23 excessComparator trialsSkeletal complicationsChronic hypophosphatemiaMusculoskeletal syndromeOngoing trialsClinical presentationTreatment modalitiesClinical trialsSUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
Murari K, Insogna K. SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2020, 4: sun-333. PMCID: PMC7207437, DOI: 10.1210/jendso/bvaa046.1470.Peer-Reviewed Original ResearchTrabecular bone scoreBone mineral densityL-spine bone mineral densityTotal hip bone mineral densityHip bone mineral densityBone scorePhase III clinical trialsRegional bone mineral densityRenal phosphate leakCourse of treatmentHuman monoclonal antibodyConsiderable clinical relevanceSignificant increaseFGF-23Frequent siteClinical trialsMineral densityMineral metabolismBone densityDrug treatmentPhosphate leakBurosumabBMD measurementsClinical relevanceStudy subjects
2018
Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia
Sullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, Chen C, Insogna KL. Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia. Calcified Tissue International 2018, 102: 666-670. PMID: 29383408, PMCID: PMC5957766, DOI: 10.1007/s00223-017-0382-0.Peer-Reviewed Original ResearchConceptsLevels of FGF23Nasal salmon calcitoninSalmon calcitoninStudy drugVisit 2Day 2Levels of PTHPrincipal outcome variableTmP/GFRSingle subcutaneous dosePlacebo nasal sprayNasal calcitoninSerum calciumSubcutaneous doseVisit 4Dihydroxyvitamin DSerum phosphorusVisit 3Final doseVisit 1Nasal sprayClinical trialsSerial measurementsDrug doseFGF23 production
2016
Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial
Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN, Investigators F. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. The Journal Of Clinical Endocrinology & Metabolism 2016, 102: 914-922. PMID: 27935736, PMCID: PMC5460686, DOI: 10.1210/jc.2016-3237.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokeFracture riskBone fracturesRisk/benefit ratioAbsolute fracture riskInsulin Resistance InterventionPlacebo-treated patientsIschemic attackNondiabetic patientsPlacebo groupCardiovascular riskBone healthStroke trialsNondiabetic participantsPrevent fallsClinical trialsRelative riskSafety dataFracture classificationQuarterly interviewsPioglitazonePatientsResistance InterventionRisk increment
2014
Supplementing a Low-Protein Diet with Dibasic Amino Acids Increases Urinary Calcium Excretion in Young Women 1,2
Bihuniak JD, Sullivan RR, Simpson CA, Caseria DM, Huedo-Medina TB, O’Brien K, Kerstetter JE, Insogna KL. Supplementing a Low-Protein Diet with Dibasic Amino Acids Increases Urinary Calcium Excretion in Young Women 1,2. Journal Of Nutrition 2014, 144: 282-288. PMID: 24431325, PMCID: PMC3927545, DOI: 10.3945/jn.113.185009.Peer-Reviewed Original ResearchConceptsIntestinal calcium absorptionLow-protein dietCalcium absorptionDual-stable calcium isotopesYoung womenUrinary calcium excretionDietary proteinControl diet periodAmino acid L-arginineHigh-protein dietAmino acid L-tryptophanCalcium excretionDiet periodClinical trialsSupplementation periodL-arginineDay 5Control dietRandom orderPhysiologic rangeDietTrialsWomenPossible benefitsL-tryptophan
2013
Dietary Protein-Induced Increases in Urinary Calcium Are Accompanied by Similar Increases in Urinary Nitrogen and Urinary Urea: A Controlled Clinical Trial
Bihuniak JD, Simpson CA, Sullivan RR, Caseria DM, Kerstetter JE, Insogna KL. Dietary Protein-Induced Increases in Urinary Calcium Are Accompanied by Similar Increases in Urinary Nitrogen and Urinary Urea: A Controlled Clinical Trial. Journal Of The Academy Of Nutrition And Dietetics 2013, 113: 447-451. PMID: 23438496, PMCID: PMC5868414, DOI: 10.1016/j.jand.2012.11.002.Peer-Reviewed Original ResearchConceptsBone turnover markersDietary protein intakeUrinary creatinineUrinary calciumProtein intakeUrinary ureaTurnover markersUrinary nitrogenNutrition intervention trialMaltodextrin controlPostmenopausal womenIntervention trialsClinical trialsUrinary metabolitesCreatinineDay 0Whey supplementationWhey supplementsIntakeSample t-testSimilar increaseTrialsT-testSupplementationMarkers
2011
Using urinary nitrogen and urea to predict dietary protein intake: a controlled clinical trial
Bihuniak J, Simpson C, Sullivan R, Kerstetter J, Insogna K. Using urinary nitrogen and urea to predict dietary protein intake: a controlled clinical trial. The FASEB Journal 2011, 25: 600.3-600.3. DOI: 10.1096/fasebj.25.1_supplement.600.3.Peer-Reviewed Original ResearchProtein intakeSupplementation trialWhey supplementationUrinary ureaBone turnover markersDietary protein intakeBone mineral densityPostmenopausal womenTurnover markersBone turnoverClinical trialsMineral densityUCreatDay 0Urine nitrogenWhey supplementsOutcome variablesIntakeTrialsMaltodextrin supplementUrinary nitrogenBone centersSupplementationSupplementsCostly alternativeDietary protein and skeletal health: a review of recent human research
Kerstetter JE, Kenny AM, Insogna KL. Dietary protein and skeletal health: a review of recent human research. Current Opinion In Lipidology 2011, 22: 16-20. PMID: 21102327, PMCID: PMC4659357, DOI: 10.1097/mol.0b013e3283419441.BooksConceptsSkeletal healthBone healthDietary proteinBone resorptionCalcium retentionInsulin-like growth factor-1Recent human researchOsteoclastic bone resorptionBone mineral densityHigh protein intakeLean body massGrowth factor-1High-protein dietMeta-analysis studyVitamin DDietary calciumCalcium absorptionCalcium metabolismBone metabolismClinical trialsMineral densityBone balanceBone massMetabolic acid loadSystemic pH
2010
Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial
Wright MJ, Sullivan RR, Gaffney‐Stomberg E, Caseria DM, O'Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial. Journal Of Bone And Mineral Research 2010, 25: 2205-2211. PMID: 20499372, PMCID: PMC3312746, DOI: 10.1002/jbmr.108.Peer-Reviewed Original ResearchConceptsIntestinal calcium absorptionProton pump inhibitorsCalcium absorptionGastric acidDual-stable calcium isotopesYoung adultsChronic PPI therapyPotent gastric acidGastric acid suppressionNegative calcium balanceGastric acid productionHealthy young adultsPPI esomeprazolePPI therapyPlacebo groupUrinary calciumAcid suppressionCrossover studyBone lossPump inhibitorsClinical trialsIntervention periodAcute effectsCalcium balanceHealthy individuals
2008
Orthopaedic Management Improves the Early Rate of Osteoporosis Treatment After Hip Fracture: A Randomized Clinical Trial
Miki R, Oetgen M, Kirk J, Insogna K, Lindskog D. Orthopaedic Management Improves the Early Rate of Osteoporosis Treatment After Hip Fracture: A Randomized Clinical Trial. Journal Of Clinical Densitometry 2008, 11: 463. DOI: 10.1016/j.jocd.2008.05.069.Peer-Reviewed Original Research